Skip NavigationSkip to Content

Loss of ubiquitin-specific peptidase 18 destabilizes 14-3-3? protein and represses lung cancer metastasis

  1. Author:
    Chen,Zibo
    Zheng, Lin
    Chen, Yulong
    Liu,Xiuxia
    Kawakami, Masanori
    Mustachio, Lisa Maria
    Roszik, Jason [ORCID]
    Ferry-Galow,Katherine
    Parchment,Ralph
    Liu, Xin
    Andresson,Thorkell
    Duncan,Gerard
    Kurie, Jonathan M
    Rodriguez-Canales, Jaime
    Liu,Xi
    Dmitrovsky,Ethan
  2. Author Address

    Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Clinical Pharmacodynamic Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Oncology and Translational Medicine, AstraZeneca, Gaithersburg, MD, USA., Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.,
    1. Year: 2022
    2. Date: Dec 31
  1. Journal: Cancer Biology & Therapy
    1. 23
    2. 1
    3. Pages: 265-280
  2. Type of Article: Article
  1. Abstract:

    Cancer metastasis is a major cause of cancer-related mortality. Strategies to reduce metastases are needed especially in lung cancer, the most common cause of cancer mortality. We previously reported increased ubiquitin-specific peptidase 18 (USP18) expression in lung and other cancers. Engineered reduction of USP18 expression repressed lung cancer growth and promoted apoptosis. This deubiquitinase (DUB) stabilized targeted proteins by removing the complex interferon-stimulated gene 15 (ISG15). This study explores if the loss of USP18 reduced lung cancer metastasis. USP18 knock-down in lung cancer cells was independently achieved using small hairpin RNAs (shRNAs) and small interfering RNAs (siRNAs). USP18 knock-down reduced lung cancer growth, wound-healing, migration, and invasion versus controls (P 160;< 160;.001) and markedly decreased murine lung cancer metastases (P 160;< 160;.001). Reverse Phase Protein Arrays (RPPAs) in shRNA knock-down lung cancer cells showed that 14-3-3? protein was regulated by loss of USP18. ISG15 complexed with 14-3-3? protein reducing its stability. Survival in lung adenocarcinomas (P 160;< 160;.0015) and other cancers was linked to elevated 14-3-3? expression as assessed by The Cancer Genome Atlas (TCGA). The findings were confirmed and extended using 14-3-3? immunohistochemical assays of human lung cancer arrays and syngeneic murine lung cancer metastasis models. A direct 14-3-3? role in controlling lung cancer metastasis came from engineered 14-3-3? knock-down in lung cancer cell lines and 14-3-3? rescue experiments that reversed migration and invasion inhibition. Findings presented here revealed that USP18 controlled metastasis by regulating 14-3-3? expression. These data provide a strong rationale for developing a USP18 inhibitor to combat metastases.

    See More

External Sources

  1. DOI: 10.1080/15384047.2022.2054242
  2. PMID: 35387560

Library Notes

  1. Fiscal Year: FY2021-2022
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel